Two Device Industry Veterans Join Boston Scientific’s Board
This article was originally published in The Gray Sheet
Executive Summary
Hologic CEO Stephen MacMillan and former Covidien exec Charles Dockendorff have been elected to Boston Scientific’s board of directors, adding significant device industry expertise to the mix. MacMillan will be the only active device industry CEO for another company on the board.
You may also be interested in...
People Briefs: Covidien CFO To Retire; Appointments At ConvaTec, Metamark, NeuroSigma, Uroplasty
Covidien Chief Financial Officer Charles Dockendorff announces retirement. ConvaTec, Metamark, NeuroSigma and Uroplasty appoint executives. More people briefs.
People Briefs: New CEO At Hologic; Departures At MDMA
Hologic appoints former Stryker CEO MacMillan president and CEO. Two staffers leave MDMA for device firms. More people briefs.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”